Science Explorer Back to mapMap
Discussion
Topic · Oncology

Lung Cancer Research Studies

Lung Cancer Research Studies is a research topic within Oncology. Science Explorer counts 38k research works in it since 1950. 10.2% of them reached the world's top 10% most cited for their field and year.

This cluster of papers represents a comprehensive exploration of small cell lung cancer, covering topics such as genomic profiles, immunotherapy, chemotherapy, prognostic factors, biomarkers, targeted therapy, clinical trials, metastasis, and tumor markers.

  • Small-Cell Lung Cancer
  • Genomic Profiles
  • Immunotherapy
  • Chemotherapy
  • Prognostic Factors
  • Biomarkers
  • Targeted Therapy
  • Clinical Trials
  • Metastasis
  • Tumor Markers
Research works
38k
fractional, since 1950
In the world top 10%
3.9k
per year above
Top-10% rate
10.2%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+19%
the tick is no change
Largest producer
China
36% of the 10 largest, 2022-now
Lung Cancer Research Studies

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Lung Cancer Research Studies research?

By volume, China and the United States publish the most (3.1k and 2.5k works in 2022-now).

By volume, 2022-now

  1. 1 China 3.1k works
  2. 2 United States 2.5k works
  3. 3 Japan 722 works
  4. 4 Italy 433 works
  5. 5 Germany 376 works
  6. 6 India 328 works
  7. 7 France 301 works
  8. 8 United Kingdom 290 works
  9. 9 South Korea 265 works
  10. 10 Spain 263 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 36.3%United States: 29.2%Japan: 8.4%Italy: 5.0%6 others listed: 21.1%36%largest
China3,139 · 36.3%United States2,523 · 29.2%Japan722 · 8.4%Italy433 · 5.0%6 others listed1,824 · 21.1%

Shares of the rows listed above, not of the whole node.

Which institutions lead Lung Cancer Research Studies research?

By volume in 2022-now, Sun Yat-sen University publishes the most Lung Cancer Research Studies research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Harvard University.

By volume, 2022-now

  1. 1 Sun Yat-sen UniversityChina 128 works
  2. 2 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 123 works
  3. 3 Harvard UniversityUnited States 115 works
  4. 4 Sichuan UniversityChina 102 works
  5. 5 Shanghai Jiao Tong UniversityChina 100 works
  6. 6 The University of Texas MD Anderson Cancer CenterUnited States 88 works
  7. 7 Shandong First Medical UniversityChina 84 works
  8. 8 Nanjing Medical UniversityChina 78 works
  9. 9 Peking UniversityChina 65 works
  10. 10 Memorial Sloan Kettering Cancer CenterUnited States 65 works

Who are the leading researchers in Lung Cancer Research Studies?

The most-cited researchers publishing on Lung Cancer Research Studies include Ahmedin Jemal, Stacey L. Gabriel and Julian P. T. Higgins.

  1. 1 Ahmedin Jemal United States 761k citations
  2. 2 Stacey L. Gabriel United States 402k citations
  3. 3 Julian P. T. Higgins United Kingdom 390k citations
  4. 4 Guido Kroemer France 386k citations
  5. 5 Bert Vogelstein United States 373k citations
  6. 6 Gad A. Getz United States 364k citations
  7. 7 Hermann Brenner Germany 343k citations
  8. 8 Jun Wang China 340k citations
  9. 9 Elie A. Akl Canada 313k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Lung Cancer Research Studies?

The most cited paper in Lung Cancer Research Studies is "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer" (Julie Renee Brahmer et al., 2015), with 8,632 citations. Next come "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" (8,331) and "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial" (5,563).

Most cited papers
#PaperReleasedCitations
1 Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Julie Renee Brahmer et al. · New England Journal of Medicine Open access 31 May 2015 8,632
2 Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony S.K. Mok, Yi-Long Lung Cancer Wu, Sumitra Thongprasert et al. · New England Journal of Medicine Open access 19 Aug 2009 8,331
3 Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell et al. · The Lancet Oncology Open access 30 Jan 2012 5,563
4 Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer Jean‐Charles Soria et al. · New England Journal of Medicine Open access 18 Nov 2017 5,475
5 Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Frances Alice Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine Open access 13 Jul 2005 5,471
All 99 most cited papers, with filters and sorting

Where is Lung Cancer Research Studies research done?

The largest centres of Lung Cancer Research Studies research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Plainview and Kashiwa.

Largest cities, 2022-now

  1. 1 BeijingChina 385 works
  2. 2 ShanghaiChina 300 works
  3. 3 GuangzhouChina 262 works
  4. 4 New YorkUnited States 178 works
  5. 5 TokyoJapan 164 works
  6. 6 SeoulSouth Korea 152 works
  7. 7 ChengduChina 149 works
  8. 8 JinanChina 146 works
  9. 9 HangzhouChina 138 works
  10. 10 NanjingChina 130 works

Where it is the local speciality

  1. PlainviewUS · 27.7 works34×
  2. KashiwaJP · 22.1 works24×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Lung Cancer Research Studies than the world average.

See Lung Cancer Research Studies on the map

Where is the best place to study Lung Cancer Research Studies?

Among universities, judged by research, Harvard University, Cornell University and Sun Yat-sen University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 15.94%fractional works in this field (log) →share of work in the world top 10% →Cornell UniversityHarvard UniversityUniversity of TorontoSun Yat-sen University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 81.521.5%4.0×115 -11.2%
2Cornell UniversityUnited States 68.723.2%2.9×34 -6.4%
3Sun Yat-sen UniversityChina 65.29.6%6.8×128 +24.9%
4University of TorontoCanada 65.015.3%2.6×48 +22.8%
5Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 63.49.1%12.8×123 +35.0%
6Sungkyunkwan UniversitySouth Korea 59.715.3%5.8×37 +12.3%
7Johns Hopkins UniversityUnited States 59.318.0%2.2×31 +0.6%
8Université Paris-SaclayFrance 58.821.2%1.6×9 +27.1%
9Southern Medical UniversityChina 58.615.7%6.3×36 +54.6%
10Nanjing Medical UniversityChina 58.510.5%9.6×78 +61.8%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Lung Cancer Research Studies, country by country

Is Lung Cancer Research Studies research growing?

Output in 2022-2025 was 19% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Lung Cancer Research Studies.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Lung Cancer Research Studies as a percentage of every work published that year, 0.040% in 2024.

still counting0.020%0.040%0.060%Lung Cancer Research Studies0.046% in 202519801990200020102020

Fractional works of Lung Cancer Research Studies over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Lung Cancer Research Studies9.9% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Questions people ask

Which institutions lead lung cancer research?

By volume in 2022-now, Sun Yat-sen University publishes the most Lung Cancer Research Studies research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Harvard University.

Which institutions lead Lung Cancer Research Studies research?
All 1,273 questions in the Question Catalogue

Discussion

Ask a question or share a note about Lung Cancer Research Studies. Posts are plain text and can be reported.